DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report released on Thursday. The brokerage set a “hold” rating on the stock.

Separately, JMP Securities restated a “market outperform” rating and set a $10.00 price objective on shares of DBV Technologies in a report on Friday, January 10th.

DBV Technologies Trading Up 3.9 %

DBVT stock opened at $8.95 on Thursday. DBV Technologies has a 1-year low of $2.20 and a 1-year high of $9.89. The business’s 50 day simple moving average is $6.37 and its 200 day simple moving average is $4.66. The firm has a market capitalization of $245.14 million, a PE ratio of -1.99 and a beta of -0.08.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings data on Friday, April 11th. The company reported ($1.10) EPS for the quarter. The company had revenue of $0.51 million during the quarter. DBV Technologies had a negative net margin of 815.73% and a negative return on equity of 106.07%. As a group, sell-side analysts predict that DBV Technologies will post -7.05 EPS for the current fiscal year.

Institutional Investors Weigh In On DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC acquired a new position in DBV Technologies S.A. (NASDAQ:DBVT) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies as of its most recent SEC filing. 71.74% of the stock is currently owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.